Bufalin reverses resistance to sorafenib by inhibiting Akt activation in hepatocellular carcinoma: The role of endoplasmic reticulum stress

PLoS ONE

Volumn 10, Issue 9, 2015, Pages

  Zhai, Bo ^a   Hu, Fengli ^a   Yan, Haijiang ^a   Zhao, Dali ^b   Jin, Xin ^a   Fang, Taishi ^a   Pan, Shangha ^b   Sun, Xueying ^b   Xu, Lishan ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b THE FIRST AFFILIATED HOSPITAL OF HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BUFALIN; GROWTH ARREST AND DNA DAMAGE INDUCIBLE PROTEIN 153; INITIATION FACTOR 2; PROTEIN IRE1; PROTEIN KINASE B; SORAFENIB; BUFADIENOLIDE DERIVATIVE; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE;

APOPTOSIS; ARTICLE; CANCER RESISTANCE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; ENDOPLASMIC RETICULUM STRESS; ENZYME ACTIVATION; ENZYME INACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; LIVER CELL CARCINOMA; MITOSIS INHIBITION; PROTEIN EXPRESSION; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; DRUG EFFECTS; DRUG RESISTANCE; HEP-G2 CELL LINE; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGY; SIGNAL TRANSDUCTION;

APOPTOSIS; BUFANOLIDES; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; DRUG RESISTANCE, NEOPLASM; ENDOPLASMIC RETICULUM STRESS; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; NIACINAMIDE; PHENYLUREA COMPOUNDS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION;

EID: 84946541893     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0138485     Document Type: Article

References (56)

1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015; 65(2):87-108.
2. Zhu AX. Systemic treatment of hepatocellular carcinoma: dawn of a new era? Annals of surgical oncology. 2010; 17(5):1247-56. doi: 10.1245/s10434-010-0975-6 PMID: 20405329
3. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib in advanced hepatocellular carcinoma. The New England journal of medicine. 2008; 359(4):378-90. doi: 10.1056/ NEJMoa0708857 PMID: 18650514
4. Zhai B, Sun XY. Mechanisms of resistance to sorafenib and the corresponding strategies in hepatocellular carcinoma. World journal of hepatology. 2013; 5(7):345-52. doi: 10.4254/wjh.v5.i7.345 PMID: 23898367
5. Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends in biochemical sciences. 2011; 36(6):320-8. doi: 10.1016/j.tibs.2011.03.006 PMID: 21531565
6. Zhou L, Huang Y, Li J, Wang Z. The mTOR pathway is associated with the poor prognosis of human hepatocellular carcinoma. Med Oncol. 2010; 27(2):255-61. doi: 10.1007/s12032-009-9201-4 PMID: 19301157
7. Zhai B, Hu F, Jiang X, Xu J, Zhao D, Liu B, et al. Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma. Molecular cancer therapeutics. 2014; 13(6):1589-98. doi: 10.1158/1535-7163.MCT-13-1043 PMID: 24705351
8. Gedaly R, Angulo P, Hundley J, Daily MF, Chen C, Koch A, et al. PI-103 and sorafenib inhibit hepatocellular carcinoma cell proliferation by blocking Ras/Raf/MAPK and PI3K/AKT/mTOR pathways. Anticancer research. 2010; 30(12):4951-8. PMID: 21187475
9. Chen KF, Chen HL, Tai WT, Feng WC, Hsu CH, Chen PJ, et al. Activation of phosphatidylinositol 3- kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells. The Journal of pharmacology and experimental therapeutics. 2011; 337(1):155-61. doi: 10.1124/ jpet.110.175786 PMID: 21205925
10. Zhai B, Jiang X, He C, Zhao D, Ma L, Xu L, et al. Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2015; 36(4):2323-34.
11. van Malenstein H, Dekervel J, Verslype C, Van Cutsem E, Windmolders P, Nevens F, et al. Long-term exposure to sorafenib of liver cancer cells induces resistance with epithelial-to-mesenchymal transition, increased invasion and risk of rebound growth. Cancer letters. 2013; 329(1):74-83. doi: 10.1016/j. canlet.2012.10.021 PMID: 23111106
12. Lackner MR, Wilson TR, Settleman J. Mechanisms of acquired resistance to targeted cancer therapies. Future Oncol. 2012; 8(8):999-1014. doi: 10.2217/fon.12.86 PMID: 22894672
13. Bottsford-Miller JN, Coleman RL, Sood AK. Resistance and escape from antiangiogenesis therapy: clinical implications and future strategies. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012; 30(32):4026-34.
14. Fan L, Sun G, Ma T, Zhong F, Lei Y, Li X, et al. Melatonin reverses tunicamycin-induced endoplasmic reticulum stress in human hepatocellular carcinoma cells and improves cytotoxic response to doxorubicin by increasing CHOP and decreasing survivin. Journal of pineal research. 2013; 55(2):184-94. doi: 10.1111/jpi.12061 PMID: 23711089
15. Jiang CC, Yang F, Thorne RF, Zhu BK, Hersey P, Zhang XD. Human melanoma cells under endoplasmic reticulum stress acquire resistance to microtubule-targeting drugs through XBP-1-mediated activation of Akt. Neoplasia. 2009; 11(5):436-47. PMID: 19412428
16. Fan L, Song B, Sun G, Ma T, Zhong F, Wei W. Endoplasmic reticulum stress-induced resistance to doxorubicin is reversed by paeonol treatment in human hepatocellular carcinoma cells. PloS one. 2013; 8(5):e62627. doi: 10.1371/journal.pone.0062627 PMID: 23658755
17. Liu N, Xu Y, Sun JT, Su J, Xiang XY, Yi HW, et al. The BH3 mimetic S1 induces endoplasmic reticulum stress-associated apoptosis in cisplatin-resistant human ovarian cancer cells although it activates autophagy. Oncology reports. 2013; 30(6):2677-84. doi: 10.3892/or.2013.2771 PMID: 24100381
18. McCloy RA, Shelley EJ, Roberts CG, Boslem E, Biden TJ, Nicholson RI, et al. Role of endoplasmic reticulum stress induction by the plant toxin, persin, in overcoming resistance to the apoptotic effects of tamoxifen in human breast cancer cells. British journal of cancer. 2013; 109(12):3034-41. doi: 10.1038/ bjc.2013.693 PMID: 24178758
19. Holz MS, Janning A, Renne C, Gattenlohner S, Spieker T, Brauninger A. Induction of endoplasmic reticulum stress by sorafenib and activation of NF-kappaB by lestaurtinib as a novel resistance mechanism in Hodgkin lymphoma cell lines. Molecular cancer therapeutics. 2013; 12(2):173-83. doi: 10. 1158/1535-7163.MCT-12-0532 PMID: 23243060
20. Brozovic A, Vukovic L, Polancac DS, Arany I, Koberle B, Fritz G, et al. Endoplasmic reticulum stress is involved in the response of human laryngeal carcinoma cells to Carboplatin but is absent in Carboplatin- resistant cells. PloS one. 2013; 8(9):e76397. doi: 10.1371/journal.pone.0076397 PMID: 24086737
21. Kato H, Nishitoh H. Stress responses from the endoplasmic reticulum in cancer. Frontiers in oncology. 2015; 5:93. doi: 10.3389/fonc.2015.00093 PMID: 25941664
22. Shi YH, Ding ZB, Zhou J, Hui B, Shi GM, Ke AW, et al. Targeting autophagy enhances sorafenib lethality for hepatocellular carcinoma via ER stress-related apoptosis. Autophagy. 2011; 7(10):1159-72. doi: 10.4161/auto.7.10.16818 PMID: 21691147
23. Hu F, Han J, Zhai B, Ming X, Zhuang L, Liu Y, et al. Blocking autophagy enhances the apoptosis effect of bufalin on human hepatocellular carcinoma cells through endoplasmic reticulum stress and JNK activation. Apoptosis: an international journal on programmed cell death. 2014; 19(1):210-23.
24. Yi P, Higa A, Taouji S, Bexiga MG, Marza E, Arma D, et al. Sorafenib-mediated targeting of the AAA(+) ATPase p97/VCP leads to disruption of the secretory pathway, endoplasmic reticulum stress, and hepatocellular cancer cell death. Molecular cancer therapeutics. 2012; 11(12):2610-20. doi: 10.1158/ 1535-7163.MCT-12-0516 PMID: 23041544
25. Meng Z, Yang P, Shen Y, Bei W, Zhang Y, Ge Y, et al. Pilot study of huachansu in patients with hepatocellular carcinoma, nonsmall-cell lung cancer, or pancreatic cancer. Cancer. 2009; 115(22):5309-18. doi: 10.1002/cncr.24602 PMID: 19701908
26. Qiu DZ, Zhang ZJ, Wu WZ, Yang YK. Bufalin, a component in Chansu, inhibits proliferation and invasion of hepatocellular carcinoma cells. BMC complementary and alternative medicine. 2013; 13:185. doi: 10.1186/1472-6882-13-185 PMID: 23870199
27. Tsai SC, Yang JS, Peng SF, Lu CC, Chiang JH, Chung JG, et al. Bufalin increases sensitivity to AKT/ mTOR-induced autophagic cell death in SK-HEP-1 human hepatocellular carcinoma cells. International journal of oncology. 2012; 41(4):1431-42. doi: 10.3892/ijo.2012.1579 PMID: 22858649
28. Zhang ZJ, Yang YK, Wu WZ. Bufalin attenuates the stage and metastatic potential of hepatocellular carcinoma in nude mice. Journal of translational medicine. 2014; 12:57. doi: 10.1186/1479-5876-12-57 PMID: 24581171
29. Wang J, Ma Y, Jiang H, Zhu H, Liu L, Sun B, et al. Overexpression of von Hippel-Lindau protein synergizes with doxorubicin to suppress hepatocellular carcinoma in mice. Journal of hepatology. 2011; 55 (2):359-68. doi: 10.1016/j.jhep.2010.10.043 PMID: 21168458
30. Sun XP, Dong X, Lin L, Jiang X, Wei Z, Zhai B, et al. Up-regulation of survivin by AKT and hypoxiainducible factor 1alpha contributes to cisplatin resistance in gastric cancer. The FEBS journal. 2014; 281(1):115-28. doi: 10.1111/febs.12577 PMID: 24165223
31. Xiu P, Dong X, Xu Z, Zhu H, Liu F, Wei Z, et al. Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma. Cancer science. 2013; 104(3):375-82. doi: 10. 1111/cas.12088 PMID: 23279642
32. Wei Z, Jiang X, Liu F, Qiao H, Zhou B, Zhai B, et al. Downregulation of Skp2 inhibits the growth and metastasis of gastric cancer cells in vitro and in vivo. Tumour biology: the journal of the International Society for Oncodevelopmental Biology and Medicine. 2013; 34(1):181-92.
33. Dong X, Li R, Xiu P, Xu Z, Zhai B, Liu F, et al. Meloxicam executes its antitumor effects against hepatocellular carcinoma in COX-2- dependent and-independent pathways. PloS one. 2014; 9(3):e92864. doi: 10.1371/journal.pone.0092864 PMID: 24675684
34. Zhao D, Zhai B, He C, Tan G, Jiang X, Pan S, et al. Upregulation of HIF-2alpha induced by sorafenib contributes to the resistance by activating the TGF-alpha/EGFR pathway in hepatocellular carcinoma cells. Cellular signalling. 2014; 26(5):1030-9. doi: 10.1016/j.cellsig.2014.01.026 PMID: 24486412
35. Jiang H, Ma Y, Chen X, Pan S, Sun B, Krissansen GW, et al. Genistein synergizes with arsenic trioxide to suppress human hepatocellular carcinoma. Cancer science. 2010; 101(4):975-83. doi: 10.1111/j. 1349-7006.2009.01464.x PMID: 20219070
36. Ma Y, Wang J, Liu L, Zhu H, Chen X, Pan S, et al. Genistein potentiates the effect of arsenic trioxide against human hepatocellular carcinoma: role of Akt and nuclear factor-kappaB. Cancer letters. 2011; 301(1):75-84. doi: 10.1016/j.canlet.2010.10.022 PMID: 21078540
37. He C, Sun XP, Qiao H, Jiang X, Wang D, Jin X, et al. Downregulating hypoxia-inducible factor-2alpha improves the efficacy of doxorubicin in the treatment of hepatocellular carcinoma. Cancer science. 2012; 103(3):528-34. doi: 10.1111/j.1349-7006.2011.02177.x PMID: 22145922
38. Qin L, Wang Z, Tao L, Wang Y. ER stress negatively regulates AKT/TSC/mTOR pathway to enhance autophagy. Autophagy. 2010; 6(2):239-47. PMID: 20104019
39. Santoro A, Rimassa L, Borbath I, Daniele B, Salvagni S, Van Laethem JL, et al. Tivantinib for secondline treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study. The Lancet Oncology. 2013; 14(1):55-63. doi: 10.1016/S1470-2045(12)70490-4 PMID: 23182627
40. Huynh H, Ngo VC, Koong HN, Poon D, Choo SP, Thng CH, et al. Sorafenib and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma. Journal of cellular and molecular medicine. 2009; 13(8B):2673-83. doi: 10.1111/j.1582-4934.2009.00692.x PMID: 19220580
41. Piguet AC, Saar B, Hlushchuk R, St-Pierre MV, McSheehy PM, Radojevic V, et al. Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma. Molecular cancer therapeutics. 2011; 10(6):1007-17. doi: 10.1158/1535-7163.MCT-10-0666 PMID: 21487053
42. Wang WA, Groenendyk J, Michalak M. Endoplasmic reticulum stress associated responses in cancer. Biochimica et biophysica acta. 2014; 1843(10):2143-9. doi: 10.1016/j.bbamcr.2014.01.012 PMID: 24440276
43. Dai R, Chen R, Li H. Cross-talk between PI3K/Akt and MEK/ERK pathways mediates endoplasmic reticulum stress-induced cell cycle progression and cell death in human hepatocellular carcinoma cells. International journal of oncology. 2009; 34(6):1749-57. PMID: 19424594
44. Chow SE, Kao CH, Liu YT, Cheng ML, Yang YW, Huang YK, et al. Resveratrol induced ER expansion and ER caspase-mediated apoptosis in human nasopharyngeal carcinoma cells. Apoptosis: an international journal on programmed cell death. 2014; 19(3):527-41.
45. Zheng YZ, Cao ZG, Hu X, Shao ZM. The endoplasmic reticulum stress markers GRP78 and CHOP predict disease-free survival and responsiveness to chemotherapy in breast cancer. Breast cancer research and treatment. 2014; 145(2):349-58. doi: 10.1007/s10549-014-2967-x PMID: 24781973
46. Lei Y, Henderson BR, Emmanuel C, Harnett PR, deFazio A. Inhibition of ANKRD1 sensitizes human ovarian cancer cells to endoplasmic reticulum stress-induced apoptosis. Oncogene. 2015; 34(4):485-95. doi: 10.1038/onc.2013.566 PMID: 24531715
47. Chen J, Wei H, Xie B, Wang B, Cheng J. Endoplasmic reticulum stress contributes to arsenic trioxideinduced apoptosis in drug-sensitive and-resistant leukemia cells. Leukemia research. 2012; 36 (12):1526-35. doi: 10.1016/j.leukres.2012.08.018 PMID: 22959511
48. Brenner C, Galluzzi L, Kepp O, Kroemer G. Decoding cell death signals in liver inflammation. Journal of hepatology. 2013; 59(3):583-94. doi: 10.1016/j.jhep.2013.03.033 PMID: 23567086
49. Gao Y, Li HX, Xu LT, Wang P, Xu LY, Cohen L, et al. Bufalin enhances the anti-proliferative effect of sorafenib on human hepatocellular carcinoma cells through downregulation of ERK. Molecular biology reports. 2012; 39(2):1683-9. doi: 10.1007/s11033-011-0908-x PMID: 21617941
50. Rong X, Ni W, Liu Y, Wen J, Qian C, Sun L, et al. Bufalin, a bioactive component of the Chinese medicine chansu, inhibits inflammation and invasion of human rheumatoid arthritis fibroblast-like synoviocytes. Inflammation. 2014; 37(4):1050-8. doi: 10.1007/s10753-014-9828-y PMID: 24515724
51. Qi F, Inagaki Y, Gao B, Cui X, Xu H, Kokudo N, et al. Bufalin and cinobufagin induce apoptosis of human hepatocellular carcinoma cells via Fas- and mitochondria-mediated pathways. Cancer science. 2011; 102(5):951-8. doi: 10.1111/j.1349-7006.2011.01900.x PMID: 21288283
52. Zhang DM, Liu JS, Tang MK, Yiu A, Cao HH, Jiang L, et al. Bufotalin from Venenum Bufonis inhibits growth of multidrug resistant HepG2 cells through G2/M cell cycle arrest and apoptosis. European journal of pharmacology. 2012; 692(1-3):19-28. doi: 10.1016/j.ejphar.2012.06.045 PMID: 22841670
53. Chen YY, Lu HF, Hsu SC, Kuo CL, Chang SJ, Lin JJ, et al. Bufalin inhibits migration and invasion in human hepatocellular carcinoma SK-Hep1 cells through the inhibitions of NF-kB and matrix metalloproteinase- 2/-9-signaling pathways. Environmental toxicology. 2015; 30(1):74-82. doi: 10.1002/tox.21896 PMID: 23949904
54. Hsu CM, Tsai Y, Wan L, Tsai FJ. Bufalin induces G2/M phase arrest and triggers autophagy via the TNF, JNK, BECN-1 and ATG8 pathway in human hepatoma cells. International journal of oncology. 2013; 43(1):338-48. doi: 10.3892/ijo.2013.1942 PMID: 23677253
55. Gu W, Liu L, Fang FF, Huang F, Cheng BB, Li B. Reversal effect of bufalin on multidrug resistance in human hepatocellular carcinoma BEL-7402/5-FU cells. Oncology reports. 2014; 31(1):216-22. doi: 10. 3892/or.2013.2817 PMID: 24173654
56. Shen S, Zhang Y, Wang Z, Liu R, Gong X. Bufalin induces the interplay between apoptosis and autophagy in glioma cells through endoplasmic reticulum stress. International journal of biological sciences. 2014; 10(2):212-24. doi: 10.7150/ijbs.8056 PMID: 24550689